A Phase 1b, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ST-617 for the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for Head and Neck Cancer
Latest Information Update: 18 Apr 2022
At a glance
- Drugs ST 617 (Primary)
- Indications Chemotherapy-induced damage; Stomatitis
- Focus Therapeutic Use
- Sponsors Supportive Therapeutics
Most Recent Events
- 06 May 2020 New trial record